Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 10/20 | 0.58 |
| ▸ | DRD3 | P35462 | 9/20 | 0.58 |
| ▸ | HTR1A | P08908 | 9/20 | 0.58 |
| ▸ | HTR2A | P28223 | 8/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.58 |
| ▸ | DRD1 | P21728 | 3/20 | 0.58 |
| ▸ | DRD5 | P21918 | 3/20 | 0.58 |
| ▸ | HRH1 | P35367 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3197906 | 0.95 | CYP2D6 (0.63) | CYP2D6HSD17B10DRD2DRD3HTR1A | |
| SCHEMBL1307372 | 0.89 | MAPT (0.58) | CYP2D6HSD17B10DRD2DRD3HTR1A | |
| SCHEMBL8011318 | 0.89 | DRD2 (0.69) | DRD2DRD3HTR1AHTR2ATMEM97 | |
| SCHEMBL16218814 | 0.84 | MAPT (0.56) | DRD2DRD3HTR1AHTR2ATMEM97 | |
| SCHEMBL10661045 | 0.83 | DRD2 (0.58) | DRD2DRD3HTR1AHTR2ATMEM97 | |
| SCHEMBL5187833 | 0.83 | CYP2D6 (0.70) | CYP2D6HSD17B10DRD2DRD3HTR1A | |
| SCHEMBL8223307 | 0.83 | KDM4E (0.62) | DRD2DRD3HTR1AHTR2ATMEM97 | |
| SCHEMBL28918989 | 0.83 | DRD2 (0.58) | DRD2DRD3HTR1AHTR2ATMEM97 | |
| SCHEMBL2095204 | 0.83 | DRD2 (0.58) | DRD2DRD3HTR1AHTR2ATMEM97 | |
| SCHEMBL11618967 | 0.83 | CYP2D6 (0.70) | CYP2D6HSD17B10DRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022509-A1 | Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-28 | — | — | US | disclosed |
| US-20100022509-A1 | Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-28 | — | — | US | disclosed |
| WO-2008036139-A2 | INHIBITORS OF MSHC AND HOMOLOGS THEREOF, AND METHODS OF IDENTIFYING SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007117180-A1 | AZAHETEROCYCLES, COMBINATORY LIBRARY, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE PRODUCTION THEREOF | 'CHEMICAL DIVERSITY RESEARCH INSTITUTE' LTD. (RU) | 2007-10-18 | — | — | WO | disclosed |
| CN-1168714-C | Arylpiperazine derivatives useful as uroselective alpha-adrenoceptor blockers | ʵ | 2004-09-29 | — | — | CN | disclosed |
| US-6420366-B1 | PERIPHERAL VASCULAR DISEASE, CONGESTIVE HEART FAILURE, HYPERTENSION AND ESPECIALLY BENIGN PROSTATIC HYPERTROPHY. | RANBAXY LABORATORIES LIMITED (IN) | 2002-07-16 | — | — | US | disclosed |
| US-6420559-B1 | THE COMPOUNDS ARE USEFUL FOR TREATMENT OF DISEASE CONDITIONS, SUCH AS PERIPHERAL VASCULAR DISEASE, CONGESTIVE HEART FAILURE, HYPERTENSION AND ESPECIALLY BENIGN PROSTATIC HYPERTROPHY. | RANBAXY LABORATORIES LIMITED (IN) | 2002-07-16 | — | — | US | disclosed |
| US-6410735-B1 | CONGESTIVE HEART FAILURE; HYPOTENSIVE AGENTS; BENGIN PROSTATIC HYPERPLASIA | RANBAXY LABORATORIES LIMITED (IN) | 2002-06-25 | — | — | US | disclosed |
| US-6359134-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| CN-1318052-A | Arylpiperazine derivatives useful as uroselective alpha-adrenoceptor blockers | RANBAXY LAB LTD (IN) | 2001-10-17 | — | — | CN | disclosed |
| US-5688795-A | URINARY TRACTS OBSTRUCTION | SYNTEX (U.S.A.) INC. (US) | 1997-11-18 | — | — | US | disclosed |
| CN-1136039-A | [3- (4-phenylpiperazin-1-yl) propylamino, thio and oxy ] -pyridine, pyrimidine and benzene derivatives | HOFFMANN LA ROCHE (CH) | 1996-11-20 | — | — | CN | disclosed |
| EP-0733040-A1 | PIPERAZINE-SUBSTITUTED PYRROLOANTHRACENE AS IMMUNO-MODERATORS | BAYER AG (DE) | 1996-09-25 | — | — | EP | disclosed |
| EP-0711757-A1 | 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy -pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists | F. Hoffmann-La Roche AG (CH) | 1996-05-15 | — | — | EP | disclosed |
| US-5461054-A | Treating rheumatoid arthritis | BAYER AKTIENGESELLSCHAFT (DE) | 1995-10-24 | — | — | US | disclosed |
| EP-0661266-A1 | Substituted cyclic amine compounds as 5HT2 antagonists | TOA EIYO LTD. (JP) | 1995-07-05 | — | — | EP | disclosed |
| WO-1995015946-A1 | PIPERAZINE-SUBSTITUTED PYRROLOANTHRACENE AS IMMUNO-MODERATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1995-06-15 | — | — | WO | disclosed |
| US-5409932-A | Antiarthritic agent for rheumatic diseases, antiinflammatory agent for gastric diseases, gastrointestinal disorders | BAYER AG (DE) | 1995-04-25 | — | — | US | disclosed |
| US-4216216-A | TREATING MIGRAINE HEADACHES, ANTI-HISTAMINES | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-08-05 | — | — | US | disclosed |
| EP-0000220-A1 | Dihydrouracils, process for their preparation and pharmaceuticals containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022509-A1 | Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same | ICMT, TST, OGA | CYP2D6 4058/4885HSD17B10 639/4885DRD2 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.